Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development

Area of Science:

• Immunology
• Autoimmunity
• T cell biology

Background:

• Autoimmune diseases are linked to regulatory T cell dysfunction.
• Peripheral double-negative (DN) T cells, activated by foreign antigens, suppress anti-donor T cells and promote graft survival.

Purpose of the Study:

• To investigate the role of DN T cells in preventing T cell-mediated autoimmune diseases.
• To determine if DN T cells can recognize self-peptides and suppress autoreactive T cells.

Main Methods:

• Utilized the P14 mouse model with a transgenic T cell receptor (TCR) specific for gp33 peptide on MHC class I-Db.
• Administered gp33 peptide to mice and analyzed T cell populations and activation markers.
• Assessed the in vitro suppressive function of DN T cells on CD8+ T cell proliferation.
• Evaluated the in vivo therapeutic potential of DN T cells in a mouse model of autoimmune diabetes.

Main Results:

• gp33 peptide administration increased DN T cell numbers and decreased CD8+ T cell numbers in lymph nodes.
• gp33 peptide, but not a non-specific peptide, activated DN T cells.
• Activated DN T cells suppressed syngeneic CD8+ T cell proliferation through antigen-specific killing.
• Transfer of activated DN T cells inhibited the development of autoimmune diabetes.

Conclusions:

• DN T cells can recognize self-peptides and suppress autoreactive CD8+ T cells in an antigen-specific manner.
• DN T cells demonstrate potential as a novel therapeutic strategy for T cell-mediated autoimmune diseases.